Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies in areas of high unmet medical need with an initial therapeutic focus in pulmonary arterial hypertension.

Altavant’s lead candidate is rodatristat ethyl*, a tryptophan hydroxylase (TPH) inhibitor. TPH inhibitors reduce the body’s peripheral production of serotonin, lowering circulating serotonin levels in diseases characterized by excessive production of the neurotransmitter, including pulmonary arterial hypertension (PAH), certain types of cancer, GI disorders, fibrosis and inflammation. Rodatristat ethyl is currently preparing for Phase 2 clinical development for pulmonary arterial hypertension with a number of additional indications being explored.

The Altavant team is passionate about building a culture that celebrates new ideas and persistence, with a deep commitment to pursue scientific innovation and novel approaches to drug development. We believe that in doing so, we can most effectively impact patients’ lives.

*name applied for; application pending


Bill Symonds, PharmD
Chief Executive Officer

Bill Symonds has served as the Chief Executive Officer of Altavant Sciences since August 2018. Prior to joining Altavant, Dr. Symonds served as Chief Development Officer of Roivant Sciences, Inc. since November 2016. He previously served as Roivant’s Senior Vice President, Clinical Research from the company’s inception in 2014 through November 2016.

Read More

From February 2012 to April 2014, Dr. Symonds served as Vice President, Liver Disease Therapeutic Area at Gilead Sciences, Inc., and he was the Senior Vice President, Clinical Pharmacology and Translational Medicine, at Pharmasset, Inc. from 2007 to January 2012. From 1993 to 2007, Dr. Symonds held various positions of increasing responsibility at GlaxoSmithKline, most recently as Director, Antiviral Clinical Pharmacology and Discovery Medicine. Dr. Symonds received his Doctor of Pharmacy degree from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory in Buffalo, New York.

Lyn Baranowski
Chief Operating Officer

Lyn Baranowski is Altavant’s Chief Operating Officer. She is a high impact biopharmaceutical industry executive with 15+ years of experience spanning biotech, big pharma, and venture capital firms. She has significant experience leading commercial, transactional, financing, and strategic functions as well as cross-functional teams across a diversity of product portfolios and therapeutic areas, ranging from preclinical to commercial stage companies. Prior to Altavant, she served as Senior Vice President,

Read More

Corporate Development & Strategy at Melinta Therapeutics, Inc. where she helped guide the company through many corporate milestones including FDA approval of the company’s lead drug, a successful corporate public listing, and an acquisition of a key business unit from the Medicines Company. Prior to that role, Ms. Baranowski served as Vice President of Commercial Development at Pearl Therapeutics which successfully developed a portfolio of COPD drugs prior to its sale to AstraZeneca for $1.15 Billion in 2013. She also worked as Vice President of Vatera Healthcare, a healthcare-focused private equity / venture capital firm based in New York, and in a variety of business development, marketing and public affairs / policy roles with Novartis Pharmaceuticals. She has an MBA from Harvard Business School and a BA from American University.

Melissa Rhodes, PhD, DABT
Chief Development Officer

Dr. Rhodes is the Chief Development Officer at Altavant Sciences, Inc. where she is responsible for leading R&D activities. Previously, she was Senior Vice President of nonclinical research (including pharmacology, toxicology, bioanalysis, and drug metabolism/pharmacokinetics) at Roivant Sciences, Inc. She has been a key contributor to >20 IND submissions and 2 NDA/MAA approvals (Tivicay and Triumeq). From 2006-2015, Dr. Rhodes held various positions of increasing responsibility

Read More

at GlaxoSmithKline, most recently as Director of nonclinical safety assessment projects in various stages of drug development. During that time, she received two GSK Pipeline Awards for key contributions to the development of integrase inhibitors for the treatment of HIV. Before joining GSK, she managed nonclinical safety assessment and DMPK for Erimos Pharmaceuticals. She completed a postdoctoral fellowship at the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences and earned her PhD from Duke University in Pharmacology/Integrated Toxicology with a focus on developmental toxicology. She received board certification from the American Board of Toxicology (DABT) in 2007.

Larry Keller, MD
VP, Clinical Development

Larry Keller has served as Vice President, Clinical Development at Altavant since August 2018. He joined Altavant from IQVIA where he was Vice President, Global Strategic Drug Development and head of the Cardiovascular Center of Excellence. Prior to IQVIA he held leadership positions in clinical R&D, medical affairs, established products, and regulatory strategy in companies including Pfizer, Kos Pharmaceuticals, Aldagen, and GlaxoSmithKline. He has focused on cardiovascular drug development

Read More

and has experience in several other therapeutic areas including rare diseases such as pulmonary arterial hypertension among others. Dr. Keller received his M.D. from The George Washington University and an M.S. in physiology from Georgetown University. He completed an internship and residency in pediatrics at The New York Hospital-Cornell Medical Center and a fellowship in pediatric cardiology at Children’s Hospital of Michigan. He became board-certified in pediatrics and pediatric cardiology and is a fellow of the American College of Cardiology.

Board of Directors

Myrtle Potter

Myrtle Potter was appointed Vant Operating Chair for Roivant Pharma in July 2018. In this role, she is expected to serve as one of two Roivant representatives on the boards of biopharmaceutical companies in the Roivant family.

Ms. Potter previously served as President and Chief Operating Officer of Genentech during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year.

Read More

Prior to Genentech she was president of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business. She is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the boards of Rite Aid and Liberty Mutual Insurance Group, and previously served on the boards of Amazon, Express Scripts, and Medco Health Solutions.

Frank Torti

Dr. Torti joined Roivant in August 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today. Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics. Dr. Torti received his M.D. from the

Read More

University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School.